SlideShare a Scribd company logo
.
PREFORMULATION
Physical properties
Mr. Tarun Parashar
Asst. prof.
Uttaranchal University
Dehradun
Preformulation unit i uips (2)
INTRODUCTION
WHAT IS PREFORMULATION?
“It is the study of the physical and chemical properties of the
drug prior to compounding process”.
• Objective :
To generate useful information to the formulator to design
an optimum drug delivery system.
• Prior to the development of any dosage form new drug, it is
essential that certain fundamental physical & chemical
properties of drug powder are determined.
• These studies should focus on physicochemical properties of
new compound that affect drug performance & development of
efficacious dosage form.
Goals of preformulation
 To establish the physicochemical parameters of a new drug.
 To establish its physical characteristics .
 To establish its compatibility with common excipients.
 Providing a scientific data to support the dosage form design and
evaluation of the product efficacy and stability.
In short
 Quantization of physical and chemical properties will assist in
developing a;
a. Stable
b. Safe
c. Effective formulation
3
4
THE MAJOR AREAS OF PREFORMULATION
STUDY
I. Physical description and Bulk Characterization:
 Crystallinity and Polymorphism
 Hygroscopicity
 Fine Particle Characterization
 Thermal Effects
 Powder Flow Properties
5
II. Solubility Analysis :
 Ionization Constant pKa
 pH Solubility Profile
 Common Ion Effect
 Solubilization
 Partition Coefficient
 Dissolution
III. Stability Analysis :
 Solid-State Stability
 Solution-Phase Stability
 Compatibility Studies: Stability in the Presence of
Excipients 6
PHYSICAL CHARACTERIZATION
 Drugs can be used therapeutically as solids, liquids
and gases.
 Liquid drugs are used to a much lesser extent than
solid drugs and even less frequently than gases.
 Solid materials are preferred in formulation work
because of their ease of preparation into tablets and
capsules.
 The majority of drug substances in use occur as solid
materials.
 Most of them are pure chemical compounds of either:
Amorphous or Crystalline in nature
7
PHYSICAL DESCRIPTION AND BULK
CHARACTERIZATION
 Bulk properties for the solid form such as particle size,
bulk density and surface morphology are likely to
change during process of development.
 The various physical and bulk characteristics are
explained as follows:
8
CRYSTALLINITY AND POLYMORPHISM
 Solid drug materials may occur as:
a. Amorphous (higher solubility)
b. Crystalline (higher stability)
 The amorphous or crystalline characters of drugs
are of great importance to its ease of formulation
and handling, its chemical stability and its
biological activity.
9
AMORPHOUS DRUGS
 Amorphous drugs have randomly arranged atoms or
molecules.
 Amorphous forms are typically prepared by ;
precipitation, lyophilization, or rapid cooling method.
Advantage:
 Amorphous forms have higher solubilities as well as
dissolution rates as compared to crystalline forms.
Disadvantage:
 Upon storage, sometimes amorphous solids tend to
revert to less stable forms. This instability can occur
during bulk processing or within dosage forms. 10
E.g. Novobiocin :
 It is inactive when administered in crystalline
form, but when they are administered in the
amorphous form, absorption from the
gastrointestinal tract proceeds rapidly with
good therapeutic response.
11
CRYSTALLINE DRUGS
 Crystals are characterized by repetitious spacing of
constituent atoms or molecules in a three dimensional
array.
 Crystalline forms of drugs may be used because of
greater stability than the corresponding amorphous
form.
 For example: the crystalline forms of penicillin G as
potassium or sodium salt is considerably more stable
and result in excellent therapeutic response than
amorphous forms.
12
POLYMORPHISM
 Polymorphism is the ability of a compound to
crystallize as more than one distinct crystalline
species with different internal lattices or crystal
packing arrangement even they are chemically
identical depending on the variation in ;
a. Temperature
b. Solvent
c. Time
13
Significance of polymorphism:
 Different polymorphs exhibits different solubilities,
therapeutic activity and stability.
 Chemical stability and solubility changes due to
polymorphism can have an impact on drug’s activity.
14
15
16
THERMAL ANALYSIS
 Differential scanning calorimetry and Differential
thermal analysis: [DSC & DTA]
Measure the heat loss or gain resulting from
physical or chemical changes within a sample as
function of temperature.
 Thermo gravimetric analysis (TGA):
It measure changes in sample weight as a function
of time (isothermal) or function of time (isothermal) or
temperature.
 Desolvation and decomposition processes are
frequently monitored by TGA. 17
Applications:
 Purity, polymorphism, solvation, degradation, and
excipient compatibility.
 Thermal analysis can be used to investigate and
predict any physicochemical interactions between
components in the formulation.
 It is used for selection of chemically compatible
excipients.
18
X-RAY DIFFRACTION
 It is an important technique for establishing the batch-
to batch reproducibility of a crystalline form.
 Each diffraction pattern is characteristic of a specific
crystalline lattice for a given compound.
Applications:
 Quantitative ratios of two polymorphs and their
percentages of crystallinity may be determined.
 Mixtures of different crystalline forms can be
analyzed using normalized intensities at specific
angles, which are unique for each crystalline form.
19
HYGROSCOPICITY
 Many drugs, particularly water-soluble salts, have a
tendency to adsorb atmospheric moisture.
 Changes in moisture level can greatly influence
many parameters such as; chemical stability,
flowability, and compatibility.
 Adsorption and equilibrium of moisture content can
depend upon; atmospheric humidity, temperature,
surface area, exposure, and the mechanism for
moisture uptake.
20
Hygroscopic substances:
It adsorbs water because of hydrate formation or
specific site adsorption.
Deliquescent materials:
Adsorb sufficient water to dissolve completely
 Analytic methods for monitoring the moisture level
are ; gravimetric (weight gained), Karl Fischer
titration, or gas chromatography) according to the
desired precision & the amount of moisture adsorbed
into the drug sample. 21
FINE PARTICLE CHARACTERIZATION
 Size, shape & surface morphology of drug particles
affect the flow property, dissolution &chemical
reactivity of drugs.
Significance of Particle Size:
 Particle size of drugs may affect formulation and
product efficacy.
 Certain physical and chemical properties of drug
substances are affected by the particle size
distribution including; drug dissolution rate, content
uniformity, texture, stability, flow characteristics,
and22 sedimentation rates.
 Particle size significantly influences the oral
absorption profiles of certain drugs.
 Satisfactory content uniformity in solid dosage
forms depends to a large degree on particle size and
the equal distribution of the active ingredient
throughout the formulation.
Particle size is characterized using these terms:
i. Very coarse (#8)
ii. Coarse (#20)
iii. Moderately coarse (#40)
iv. Fine (#60)
v. Very fine (#80)
Particle size can influence variety of important
factors:
- Dissolution rate
- Suspendability
- Uniform distribution
- Penetrability
- Lack of grittiness
Methods to Determine Particle Size
• Sieving
• Microscopy
• Sedimentation rate method
• Light energy diffraction
• Laser holography
• Cascade impaction
1. Sieving method :
• Range : 50 – 150 µm
• Simple, inexpensive
• If powder is not dry, the apertures get clogged.
2. Microscopy :
• Range : 0.2 – 100 µm
• Particle size can be determined by the use of
calibrated grid background.
• Most direct method.
• Slow & tedious method.
3. Sedimentation method :
• Range : 1 - 200 µm
• Andreasen pipette is used.
4. Cascade impaction :
• The principle that a particle driven by an
airstream will hit a surface in its path, provide
that its inertia is sufficient to overcome the drug
force that tends to keep in it in airstream.
5. Light energy diffraction :
• Range : 0.5 – 500 µm
• Particle size is determined by the reduction in
light reaching the sensor as the particle,
dispersed in a liquid or gas, passes through the
sensing zone.
• Quick & fast.
6. Laser holography :
• Range : 1.4 – 100 µm
• A pulsed laser is fired through an aerosolized
particle spray & photographed in three
dimensional with holographic camera, allowing
the particles to be individually imaged & sized.
23
27
SURFACE MORPHOLOGY
 It is observed by Scanning Electron Microscopy
(SEM), which serves to confirm the physical
observations related to surface area.
 Surface morphology of drug can provide greater
area for various surface reactions such as;
degradation, dissolution, or hygroscopicity.
 Surface roughness leads to poor powder flow
characteristics of powders due to friction and
cohesiveness
28
BULK DENSITY
 Bulk density of a compound varies with the method
of crystallization, milling, or formulation.
Importance of bulk density:
 Knowledge of the true and bulk densities of the drug
substance is useful in forming idea about the size of
the final dosage form.
 The density of solids also affects their flow
properties.
29
POWDER FLOW PROPERTIES
 Flow properties are significantly affected by:
Changes in particle size, density, shape, and
adsorbed moisture, which may arise from
processing or formulation.
 The powder flow properties can be characterized
by the following methods:
30
The Angle Of Repose:
 It is the maximum angle between the surface of a pile
of powder and horizontal plane
Tan θ= h/r
 The rougher and more irregular the surface of the
particles, the higher will be the angle of repose.
 Lower values indicates better flow characteristics.
31
The acceptance criteria for angle of repose are:
Angle of repose Type of flow
< 20 Excellent flow
20-30 Good flow
30-34 Passable
>40 Poor flow
32
 Compressibility:
It can be characterized by the following methods;
1. Carr’s compressibility index
2. Hausner`s ratio
1. Carr’s compressibility index:
Carr’s index (%) =Tapped density–bulk density x100
Tapped density
 By decreasing the bulk and tapped density good flow
properties can be obtained.
33
The acceptance criteria for carr`s index are :
Carr’s index Type of flow
5-15 Excellent
12-16 Good
18-21 Fair to passable
23-35 Poor
33-38 Very poor
>40 Extremely poor
2. Hausner `s ratio:
 Hausner `s ratio = Tapped density X 100
bulk density
The acceptance criteria for Hausner`s ratio are :
:
Hausner`s ratio Type of flow
< 1.25 Good flow
> 1.5 Poor flow
1.25-1.5 Glidant addition required
>1.5 Glidant doesn’t improve
flow
SOLUBILITY
 The solubility of drug is an important
physicochemical property because it affects the rate of
drug release into the dissolution medium and
consequently, the therapeutic efficacy of the
pharmaceutical product.
 The solubility of a material is usually determined by
the equilibrium solubility method, which employs a
saturated solution of the material, obtained by stirring
an excess of material in the solvent for a prolonged
period until equilibrium is achieved.
 General rules –
➢ 1. Polar solutes dissolve in polar solvents 36
➢ 2. Non-polar solutes dissolve in non-polar solvents
Common solvents used for solubility determination are:
 Water

 Polyethylene Glycols

 Propylene Glycol

 Glycerine

 Sorbitol

 Ethyl Alcohol

 Methanol

 Benzyl Alcohol

 Isopropyl Alcohol

 Tweens

 Polysorbates

 Castor Oil

 Peanut Oil
 Sesame Oil
37
Buffers at various pHs
SOLUBILITY DETERMINATION
Description Approximate Solubility(%w/v)
weight of
solvent(g)
necessary to
dissolve 1g of
solute
Very soluble <1 10-50
Freely soluble 1-10 3.3-10
Soluble 10-30 1-3.3
Sparingly soluble 30-100 0.1-1
Slightly soluble 100-1000 0.01-.1
Very slightly soluble 1000-10000 0.01-0.1 38
Poorly soluble >10000 <0.01
Ionization constant (pKa)
 For a compound containing basic or acidic functional
groups, solubility at a given pH is influenced by the
compound’s ionization characteristics.
 The solubility of a compound in aqueous media is
greater in the ionized state than in the neutral state.
 Thus, solubility of ionizable compounds is
dependent on the pH of the solution.
 The method for the determination of pKa according
to the nature of drug can be explained as:
39
pKa Determination By Nature of
Drug
Nature of drug Ionization pKa
Very weak acid Unionized at all pH >8
Moderately weak Unionized at 2.5-7.3
acid gastric pH-1.2
Strong acid Ionize at all pH <2.5
Very weak base Unionize at all pH <5
Moderately weak Unionize at 5-11
base intestinal pH
Strong base Ionize at all pH >11
40
 Determination of the dissociation constant for a drug
capable of ionization within a pH range of 1 to 10 is
important since solubility, and consequently
absorption, can be altered by changing pH.
 The Henderson-Hasselbalch equation provides an
estimate of the ionized and un-ionized drug
concentration at a particular pH.
 For acidic compounds:
pH = pKa + log ([ionized drug]/[un-ionized drug])
 For basic compounds:
pH = pKb + log ([ionized drug]/[un-ionized drug])
Methods for determination of pKa:
The various methods for the determination of pKa are;
a. Potentiometric method
b. Spectrophotometric method
c. Solubility method
d. Conductometric method
42
Partition coefficient
 Partition coefficient (oil/water) is a measure of a
drug's lipophilicity and an indication of its ability to
cross cell membranes.
Define:
It is defined as the ratio of un-ionized drug
distributed between the organic and aqueous phases
at equilibrium.
Drugs having values of P much greater than 1 are
classified as lipophilic, whereas those with partition
coefficients much less than 1 are indicative of a43
hydrophilic drug
Stability studies
 Preformulation stability studies are usually the first
quantitative assessment of chemical stability of a
new drug.
 These studies include both solution and solid state
experiments under conditions typical for the
handling, formulation, storage, and administration of
a drug candidate as well as stability in presence of
other excipients.
 Factors affecting chemical stability critical in
rational dosage form design include ;
➢ Temperature
➢pH
➢Dosage form diluents
 The effect of pH on drug stability is important in the
development of both oral and parenteral dosage
forms
 Buffer selection for parenteral dosage forms will
also be largely based on the stability characteristics
of the drug.
Preformulation unit i uips (2)

More Related Content

PPTX
Consolidation seminar......
PPTX
Formulation Additives
PPTX
Saivani ppt
PPT
Controlled Release Oral Drug Delivery System
PPT
solid dispersion
PPTX
Parameters in Preformulation Studies
PPT
Techniques for enhancement of dissolution rate
Consolidation seminar......
Formulation Additives
Saivani ppt
Controlled Release Oral Drug Delivery System
solid dispersion
Parameters in Preformulation Studies
Techniques for enhancement of dissolution rate

What's hot (20)

PPTX
Controlled release drug delivery system
PPT
Tablet coating process
PPT
Preformulation
PPTX
factors affecting dissolution rate a full view.
PPTX
Master formula record
PPTX
preformulation
PPT
PPTX
Parenteral formulations
PDF
Drug excipient Compatibility
PPTX
Physics of tablet compression
PDF
Phase solubility analysis and pH solubility profile
PPT
Microencapsulation (2)
PPT
Preformulation
PPTX
Physics of tablet compression
PPTX
Fluidized bed processing
PPTX
Bcs classification by sneha gaurkar
PPTX
Dissolution models
PPT
Dissolution testing
PPTX
Controlled release drug delivery system
Tablet coating process
Preformulation
factors affecting dissolution rate a full view.
Master formula record
preformulation
Parenteral formulations
Drug excipient Compatibility
Physics of tablet compression
Phase solubility analysis and pH solubility profile
Microencapsulation (2)
Preformulation
Physics of tablet compression
Fluidized bed processing
Bcs classification by sneha gaurkar
Dissolution models
Dissolution testing
Ad

Similar to Preformulation unit i uips (2) (20)

PPTX
Preformulation and physicochemical property of the drug
PPTX
PREFORMULATION.pptx
PPTX
UNIT-I Preformulation. INDUSTRAIL PHARMACY -1pptx
PPTX
Preformulation Power Point Presentation
PPTX
Pre-formulation_studies M. Pharm Pharmacutics SEM I
PPTX
Preformulation Studies of Herbal Cosmetics
PPTX
Preformulation studies
PPT
0 preformulation (1)
PPTX
Preformlation
PPTX
UNIT 1 - PREFORMULATION.pptx
PPTX
Preformation supriya
PPTX
Preformulation Studies
PPTX
preformulatiom of drugs and it's characterization.
PPTX
Preformulation study ppt
PPTX
Preformulation.pptx
PPTX
preformulation study during drug development .pptx
PPTX
PPTX
PREFORMULATION STUDY IN DESIGNING OF TABLET DOSAGES FORM.pptx
Preformulation and physicochemical property of the drug
PREFORMULATION.pptx
UNIT-I Preformulation. INDUSTRAIL PHARMACY -1pptx
Preformulation Power Point Presentation
Pre-formulation_studies M. Pharm Pharmacutics SEM I
Preformulation Studies of Herbal Cosmetics
Preformulation studies
0 preformulation (1)
Preformlation
UNIT 1 - PREFORMULATION.pptx
Preformation supriya
Preformulation Studies
preformulatiom of drugs and it's characterization.
Preformulation study ppt
Preformulation.pptx
preformulation study during drug development .pptx
PREFORMULATION STUDY IN DESIGNING OF TABLET DOSAGES FORM.pptx
Ad

Recently uploaded (20)

PDF
Anesthesia in Laparoscopic Surgery in India
PDF
Saundersa Comprehensive Review for the NCLEX-RN Examination.pdf
PDF
VCE English Exam - Section C Student Revision Booklet
PDF
102 student loan defaulters named and shamed – Is someone you know on the list?
PDF
Classroom Observation Tools for Teachers
PDF
grade 11-chemistry_fetena_net_5883.pdf teacher guide for all student
PDF
3rd Neelam Sanjeevareddy Memorial Lecture.pdf
PPTX
Introduction_to_Human_Anatomy_and_Physiology_for_B.Pharm.pptx
PPTX
human mycosis Human fungal infections are called human mycosis..pptx
PDF
Supply Chain Operations Speaking Notes -ICLT Program
PDF
Business Ethics Teaching Materials for college
PPTX
Institutional Correction lecture only . . .
PPTX
Pharma ospi slides which help in ospi learning
PPTX
Final Presentation General Medicine 03-08-2024.pptx
PPTX
Renaissance Architecture: A Journey from Faith to Humanism
PDF
Mark Klimek Lecture Notes_240423 revision books _173037.pdf
PPTX
school management -TNTEU- B.Ed., Semester II Unit 1.pptx
PPTX
Week 4 Term 3 Study Techniques revisited.pptx
PPTX
IMMUNITY IMMUNITY refers to protection against infection, and the immune syst...
PDF
Chapter 2 Heredity, Prenatal Development, and Birth.pdf
Anesthesia in Laparoscopic Surgery in India
Saundersa Comprehensive Review for the NCLEX-RN Examination.pdf
VCE English Exam - Section C Student Revision Booklet
102 student loan defaulters named and shamed – Is someone you know on the list?
Classroom Observation Tools for Teachers
grade 11-chemistry_fetena_net_5883.pdf teacher guide for all student
3rd Neelam Sanjeevareddy Memorial Lecture.pdf
Introduction_to_Human_Anatomy_and_Physiology_for_B.Pharm.pptx
human mycosis Human fungal infections are called human mycosis..pptx
Supply Chain Operations Speaking Notes -ICLT Program
Business Ethics Teaching Materials for college
Institutional Correction lecture only . . .
Pharma ospi slides which help in ospi learning
Final Presentation General Medicine 03-08-2024.pptx
Renaissance Architecture: A Journey from Faith to Humanism
Mark Klimek Lecture Notes_240423 revision books _173037.pdf
school management -TNTEU- B.Ed., Semester II Unit 1.pptx
Week 4 Term 3 Study Techniques revisited.pptx
IMMUNITY IMMUNITY refers to protection against infection, and the immune syst...
Chapter 2 Heredity, Prenatal Development, and Birth.pdf

Preformulation unit i uips (2)

  • 1. . PREFORMULATION Physical properties Mr. Tarun Parashar Asst. prof. Uttaranchal University Dehradun
  • 3. INTRODUCTION WHAT IS PREFORMULATION? “It is the study of the physical and chemical properties of the drug prior to compounding process”. • Objective : To generate useful information to the formulator to design an optimum drug delivery system. • Prior to the development of any dosage form new drug, it is essential that certain fundamental physical & chemical properties of drug powder are determined. • These studies should focus on physicochemical properties of new compound that affect drug performance & development of efficacious dosage form.
  • 4. Goals of preformulation  To establish the physicochemical parameters of a new drug.  To establish its physical characteristics .  To establish its compatibility with common excipients.  Providing a scientific data to support the dosage form design and evaluation of the product efficacy and stability. In short  Quantization of physical and chemical properties will assist in developing a; a. Stable b. Safe c. Effective formulation 3
  • 5. 4
  • 6. THE MAJOR AREAS OF PREFORMULATION STUDY I. Physical description and Bulk Characterization:  Crystallinity and Polymorphism  Hygroscopicity  Fine Particle Characterization  Thermal Effects  Powder Flow Properties 5
  • 7. II. Solubility Analysis :  Ionization Constant pKa  pH Solubility Profile  Common Ion Effect  Solubilization  Partition Coefficient  Dissolution III. Stability Analysis :  Solid-State Stability  Solution-Phase Stability  Compatibility Studies: Stability in the Presence of Excipients 6
  • 8. PHYSICAL CHARACTERIZATION  Drugs can be used therapeutically as solids, liquids and gases.  Liquid drugs are used to a much lesser extent than solid drugs and even less frequently than gases.  Solid materials are preferred in formulation work because of their ease of preparation into tablets and capsules.  The majority of drug substances in use occur as solid materials.  Most of them are pure chemical compounds of either: Amorphous or Crystalline in nature 7
  • 9. PHYSICAL DESCRIPTION AND BULK CHARACTERIZATION  Bulk properties for the solid form such as particle size, bulk density and surface morphology are likely to change during process of development.  The various physical and bulk characteristics are explained as follows: 8
  • 10. CRYSTALLINITY AND POLYMORPHISM  Solid drug materials may occur as: a. Amorphous (higher solubility) b. Crystalline (higher stability)  The amorphous or crystalline characters of drugs are of great importance to its ease of formulation and handling, its chemical stability and its biological activity. 9
  • 11. AMORPHOUS DRUGS  Amorphous drugs have randomly arranged atoms or molecules.  Amorphous forms are typically prepared by ; precipitation, lyophilization, or rapid cooling method. Advantage:  Amorphous forms have higher solubilities as well as dissolution rates as compared to crystalline forms. Disadvantage:  Upon storage, sometimes amorphous solids tend to revert to less stable forms. This instability can occur during bulk processing or within dosage forms. 10
  • 12. E.g. Novobiocin :  It is inactive when administered in crystalline form, but when they are administered in the amorphous form, absorption from the gastrointestinal tract proceeds rapidly with good therapeutic response. 11
  • 13. CRYSTALLINE DRUGS  Crystals are characterized by repetitious spacing of constituent atoms or molecules in a three dimensional array.  Crystalline forms of drugs may be used because of greater stability than the corresponding amorphous form.  For example: the crystalline forms of penicillin G as potassium or sodium salt is considerably more stable and result in excellent therapeutic response than amorphous forms. 12
  • 14. POLYMORPHISM  Polymorphism is the ability of a compound to crystallize as more than one distinct crystalline species with different internal lattices or crystal packing arrangement even they are chemically identical depending on the variation in ; a. Temperature b. Solvent c. Time 13
  • 15. Significance of polymorphism:  Different polymorphs exhibits different solubilities, therapeutic activity and stability.  Chemical stability and solubility changes due to polymorphism can have an impact on drug’s activity. 14
  • 16. 15
  • 17. 16
  • 18. THERMAL ANALYSIS  Differential scanning calorimetry and Differential thermal analysis: [DSC & DTA] Measure the heat loss or gain resulting from physical or chemical changes within a sample as function of temperature.  Thermo gravimetric analysis (TGA): It measure changes in sample weight as a function of time (isothermal) or function of time (isothermal) or temperature.  Desolvation and decomposition processes are frequently monitored by TGA. 17
  • 19. Applications:  Purity, polymorphism, solvation, degradation, and excipient compatibility.  Thermal analysis can be used to investigate and predict any physicochemical interactions between components in the formulation.  It is used for selection of chemically compatible excipients. 18
  • 20. X-RAY DIFFRACTION  It is an important technique for establishing the batch- to batch reproducibility of a crystalline form.  Each diffraction pattern is characteristic of a specific crystalline lattice for a given compound. Applications:  Quantitative ratios of two polymorphs and their percentages of crystallinity may be determined.  Mixtures of different crystalline forms can be analyzed using normalized intensities at specific angles, which are unique for each crystalline form. 19
  • 21. HYGROSCOPICITY  Many drugs, particularly water-soluble salts, have a tendency to adsorb atmospheric moisture.  Changes in moisture level can greatly influence many parameters such as; chemical stability, flowability, and compatibility.  Adsorption and equilibrium of moisture content can depend upon; atmospheric humidity, temperature, surface area, exposure, and the mechanism for moisture uptake. 20
  • 22. Hygroscopic substances: It adsorbs water because of hydrate formation or specific site adsorption. Deliquescent materials: Adsorb sufficient water to dissolve completely  Analytic methods for monitoring the moisture level are ; gravimetric (weight gained), Karl Fischer titration, or gas chromatography) according to the desired precision & the amount of moisture adsorbed into the drug sample. 21
  • 23. FINE PARTICLE CHARACTERIZATION  Size, shape & surface morphology of drug particles affect the flow property, dissolution &chemical reactivity of drugs. Significance of Particle Size:  Particle size of drugs may affect formulation and product efficacy.  Certain physical and chemical properties of drug substances are affected by the particle size distribution including; drug dissolution rate, content uniformity, texture, stability, flow characteristics, and22 sedimentation rates.
  • 24.  Particle size significantly influences the oral absorption profiles of certain drugs.  Satisfactory content uniformity in solid dosage forms depends to a large degree on particle size and the equal distribution of the active ingredient throughout the formulation. Particle size is characterized using these terms: i. Very coarse (#8) ii. Coarse (#20) iii. Moderately coarse (#40) iv. Fine (#60) v. Very fine (#80)
  • 25. Particle size can influence variety of important factors: - Dissolution rate - Suspendability - Uniform distribution - Penetrability - Lack of grittiness Methods to Determine Particle Size • Sieving • Microscopy • Sedimentation rate method • Light energy diffraction • Laser holography • Cascade impaction
  • 26. 1. Sieving method : • Range : 50 – 150 µm • Simple, inexpensive • If powder is not dry, the apertures get clogged. 2. Microscopy : • Range : 0.2 – 100 µm • Particle size can be determined by the use of calibrated grid background. • Most direct method. • Slow & tedious method. 3. Sedimentation method : • Range : 1 - 200 µm • Andreasen pipette is used. 4. Cascade impaction :
  • 27. • The principle that a particle driven by an airstream will hit a surface in its path, provide that its inertia is sufficient to overcome the drug force that tends to keep in it in airstream. 5. Light energy diffraction : • Range : 0.5 – 500 µm • Particle size is determined by the reduction in light reaching the sensor as the particle, dispersed in a liquid or gas, passes through the sensing zone. • Quick & fast. 6. Laser holography : • Range : 1.4 – 100 µm
  • 28. • A pulsed laser is fired through an aerosolized particle spray & photographed in three dimensional with holographic camera, allowing the particles to be individually imaged & sized. 23 27
  • 29. SURFACE MORPHOLOGY  It is observed by Scanning Electron Microscopy (SEM), which serves to confirm the physical observations related to surface area.  Surface morphology of drug can provide greater area for various surface reactions such as; degradation, dissolution, or hygroscopicity.  Surface roughness leads to poor powder flow characteristics of powders due to friction and cohesiveness 28
  • 30. BULK DENSITY  Bulk density of a compound varies with the method of crystallization, milling, or formulation. Importance of bulk density:  Knowledge of the true and bulk densities of the drug substance is useful in forming idea about the size of the final dosage form.  The density of solids also affects their flow properties. 29
  • 31. POWDER FLOW PROPERTIES  Flow properties are significantly affected by: Changes in particle size, density, shape, and adsorbed moisture, which may arise from processing or formulation.  The powder flow properties can be characterized by the following methods: 30
  • 32. The Angle Of Repose:  It is the maximum angle between the surface of a pile of powder and horizontal plane Tan θ= h/r  The rougher and more irregular the surface of the particles, the higher will be the angle of repose.  Lower values indicates better flow characteristics. 31
  • 33. The acceptance criteria for angle of repose are: Angle of repose Type of flow < 20 Excellent flow 20-30 Good flow 30-34 Passable >40 Poor flow 32
  • 34.  Compressibility: It can be characterized by the following methods; 1. Carr’s compressibility index 2. Hausner`s ratio 1. Carr’s compressibility index: Carr’s index (%) =Tapped density–bulk density x100 Tapped density  By decreasing the bulk and tapped density good flow properties can be obtained. 33
  • 35. The acceptance criteria for carr`s index are : Carr’s index Type of flow 5-15 Excellent 12-16 Good 18-21 Fair to passable 23-35 Poor 33-38 Very poor >40 Extremely poor
  • 36. 2. Hausner `s ratio:  Hausner `s ratio = Tapped density X 100 bulk density The acceptance criteria for Hausner`s ratio are : : Hausner`s ratio Type of flow < 1.25 Good flow > 1.5 Poor flow 1.25-1.5 Glidant addition required >1.5 Glidant doesn’t improve flow
  • 37. SOLUBILITY  The solubility of drug is an important physicochemical property because it affects the rate of drug release into the dissolution medium and consequently, the therapeutic efficacy of the pharmaceutical product.  The solubility of a material is usually determined by the equilibrium solubility method, which employs a saturated solution of the material, obtained by stirring an excess of material in the solvent for a prolonged period until equilibrium is achieved.  General rules – ➢ 1. Polar solutes dissolve in polar solvents 36 ➢ 2. Non-polar solutes dissolve in non-polar solvents
  • 38. Common solvents used for solubility determination are:  Water   Polyethylene Glycols   Propylene Glycol   Glycerine   Sorbitol   Ethyl Alcohol   Methanol   Benzyl Alcohol   Isopropyl Alcohol   Tweens   Polysorbates   Castor Oil   Peanut Oil  Sesame Oil 37 Buffers at various pHs
  • 39. SOLUBILITY DETERMINATION Description Approximate Solubility(%w/v) weight of solvent(g) necessary to dissolve 1g of solute Very soluble <1 10-50 Freely soluble 1-10 3.3-10 Soluble 10-30 1-3.3 Sparingly soluble 30-100 0.1-1 Slightly soluble 100-1000 0.01-.1 Very slightly soluble 1000-10000 0.01-0.1 38 Poorly soluble >10000 <0.01
  • 40. Ionization constant (pKa)  For a compound containing basic or acidic functional groups, solubility at a given pH is influenced by the compound’s ionization characteristics.  The solubility of a compound in aqueous media is greater in the ionized state than in the neutral state.  Thus, solubility of ionizable compounds is dependent on the pH of the solution.  The method for the determination of pKa according to the nature of drug can be explained as: 39
  • 41. pKa Determination By Nature of Drug Nature of drug Ionization pKa Very weak acid Unionized at all pH >8 Moderately weak Unionized at 2.5-7.3 acid gastric pH-1.2 Strong acid Ionize at all pH <2.5 Very weak base Unionize at all pH <5 Moderately weak Unionize at 5-11 base intestinal pH Strong base Ionize at all pH >11 40
  • 42.  Determination of the dissociation constant for a drug capable of ionization within a pH range of 1 to 10 is important since solubility, and consequently absorption, can be altered by changing pH.  The Henderson-Hasselbalch equation provides an estimate of the ionized and un-ionized drug concentration at a particular pH.  For acidic compounds: pH = pKa + log ([ionized drug]/[un-ionized drug])  For basic compounds: pH = pKb + log ([ionized drug]/[un-ionized drug])
  • 43. Methods for determination of pKa: The various methods for the determination of pKa are; a. Potentiometric method b. Spectrophotometric method c. Solubility method d. Conductometric method 42
  • 44. Partition coefficient  Partition coefficient (oil/water) is a measure of a drug's lipophilicity and an indication of its ability to cross cell membranes. Define: It is defined as the ratio of un-ionized drug distributed between the organic and aqueous phases at equilibrium. Drugs having values of P much greater than 1 are classified as lipophilic, whereas those with partition coefficients much less than 1 are indicative of a43 hydrophilic drug
  • 45. Stability studies  Preformulation stability studies are usually the first quantitative assessment of chemical stability of a new drug.  These studies include both solution and solid state experiments under conditions typical for the handling, formulation, storage, and administration of a drug candidate as well as stability in presence of other excipients.  Factors affecting chemical stability critical in rational dosage form design include ; ➢ Temperature ➢pH ➢Dosage form diluents
  • 46.  The effect of pH on drug stability is important in the development of both oral and parenteral dosage forms  Buffer selection for parenteral dosage forms will also be largely based on the stability characteristics of the drug.